We tested samples from PiD, PSP, CBD, and controls (Fig. 4D) and found that clone 18 indeed did not show enhanced sensitivity for non-AD tau, since the signal was observed to remain low in other tauopathies (despite matching for equivalent amounts of tau added to the assay). This evidence concerns the gene MAPT and Alzheimer disease.